Amanda Jones

1 presentation

• T84. IMPACT-2: A PHASE 2 RANDOMIZED, DOSE-RESPONSE TRIAL OF TSND-201 (METHYLONE) FOR THE TREATMENT OF PTSD

  2026 ASCP Annual Meeting